Skip to main content

Murad Hussain is a trial and appellate attorney who represents individuals and entities in all stages of government investigations, False Claims Act (FCA) and other complex civil litigation, criminal prosecutions, and internal compliance reviews. He defends life sciences innovators, healthcare providers, government contractors, and others facing allegations of healthcare fraud, procurement fraud, kickbacks and bribery, and regulatory non-compliance. He also advises multinational organizations and others on compliance with the Foreign Agents Registration Act (FARA) and related U.S. Department of Justice (DOJ) inquiries. Across his practice, Murad has successfully defended clients in federal criminal jury trials, won dismissals of FCA qui tam lawsuits, and secured declinations and no-fault settlements for individuals and entities under investigation by Main Justice, U.S. Attorney's Offices, the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), the Small Business Administration (SBA), other federal agencies, and state Attorneys General.

Murad has been recognized by Best Lawyers for FCA qui tam defense and white collar criminal defense, by The Legal 500 as a “Next Generation Partner” for healthcare and life sciences matters, and by the Outpatient Endovascular and Interventional Society (OEIS) as a “Distinguished Friend.” He serves on the firm's Pro Bono Committee, as the partner editor for the firm's Enforcement Edge blog, and as an Adjunct Professor of trial practice at the Georgetown University Law Center, and he was recently appointed by Virginia Supreme Court Chief Justice S. Bernard Goodwyn to serve on the faculty for the Virginia State Bar Harry L. Carrico Professionalism Course. Murad also regularly publishes and speaks on FCA, FARA, and data analytics-related enforcement matters.

Murad served as a law clerk to the Honorable Ellen Segal Huvelle of the U.S. District Court for the District of Columbia. He earned his law degree from Yale Law School, where he received the Potter Stewart Prize for best moot court team and the President's Public Service Fellowship. Before law school, he worked as a creative executive at a Hollywood studio-based production company.

Experience

  • Pharmaceutical innovators, in winning dismissals of two False Claims Act qui tam suits concerning Plavix promotional activities, litigating related federal and state appeals, and securing nuisance-value settlements in parallel consumer protection litigation by state Attorneys General. U.S. ex rel. JKJ Partnership 2011 LLP v. Sanofi Aventis, U.S. LLC, et al., No. 3:11-CV-6476, 2021 WL 5002715 (D.N.J. Oct. 28, 2021), on remand from 974 F.3d 228 (3d Cir.), after certified question answered by 226 A.3d 1117 (Del. 2020), upon certification from 2019 WL 10271190 (3d Cir. 2019), on appeal from 315 F. Supp. 3d 817 (DNJ 2018); U.S. ex rel. Dickson v. Bristol-Myers Squibb Co., et al., 332 F. Supp. 3d 927 (D.N.J. 2017); West Virginia ex rel. Morrisey v. Bristol-Myers Co., et al., No. 12-C-266H (W. Va. Cir. Ct., Marshall Cty.); Hood ex rel. Mississippi v. Bristol-Myers Squib Co., et al., No. 2014-2124 (Miss. Ch. Ct., Chickasaw Cty.).
  • Biopharmaceutical company, in defending against a corporate relator's False Claims Act qui tam suit concerning nurse educator and reimbursement services. U.S. ex rel. CIMZNHCA LLC v. UCB Inc., 970 F.3d 835 (7th Cir. 2020) (ordering dismissal over relator's objections), rev'g No. 17-CV-765, 2019 WL 1598109 (S.D. Ill. Apr. 15, 2019).
  • Global healthcare company, in a DOJ investigation of Anti-Kickback Statute (AKS) and price reporting compliance by pharmacy benefit managers (PBMs).
  • Biopharmaceutical company, in conducting an internal review of Lacey Act compliance concerning research animal transactions.
  • Multinational pharmaceutical company, in counseling on U.S. customs compliance for imported products.
  • Pharmaceutical innovator, in defending against an antitrust class action based on allegations of sham patent infringement litigation.
  • Various life sciences companies, in bringing administrative litigation to challenge Medicare civil monetary penalty determinations and negotiating nuisance-value no-fault settlements.
  • Various medical device companies, in advising on Administrative Procedure Act litigation challenges to Medicare rulemaking and local coverage determinations.
  • Multiple pharmaceutical companies, in responding to third-party subpoenas in civil FCA qui tam litigation.
  • Pharmaceutical company, in advising on state anti-kickback laws related to consumer marketing.

Recognition

Best Lawyers
Qui Tam Law (Washington, D.C.) (2021-2025)
Criminal Defense: White Collar (Washington, D.C.) (2023)
The Legal 500 US
"Next Generation Partner" Healthcare: Life Sciences (2020-2023)
Healthcare: Life Sciences (2021-2022)
Healthcare: Service Providers (2021)
Washington, DC Super Lawyers
"Rising Star"Criminal Defense: White Collar; Government Contracts; Health Care; Civil Litigation: Defense (20142017)

Credentials

Education

  • J.D., Yale Law School
  • A.B., Harvard College, magna cum laude

Admissions

  • District of Columbia
  • California
  • Virginia
  • U.S. Court of Appeals for the District of Columbia Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Fourth Circuit
  • U.S. Court of Appeals for the Eleventh Circuit
  • U.S. District Court, District of Columbia
  • U.S. District Court, Central District of California
  • U.S. District Court, Eastern District of Virginia

Clerkships

  • U.S. District Court, District of Columbia, The Honorable Ellen Segal Huvelle
Overview